Christopher Pocock

5.9k total citations · 1 hit paper
64 papers, 2.1k citations indexed

About

Christopher Pocock is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Christopher Pocock has authored 64 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Genetics, 33 papers in Pathology and Forensic Medicine and 30 papers in Hematology. Recurrent topics in Christopher Pocock's work include Lymphoma Diagnosis and Treatment (32 papers), Chronic Lymphocytic Leukemia Research (30 papers) and Chronic Myeloid Leukemia Treatments (18 papers). Christopher Pocock is often cited by papers focused on Lymphoma Diagnosis and Treatment (32 papers), Chronic Lymphocytic Leukemia Research (30 papers) and Chronic Myeloid Leukemia Treatments (18 papers). Christopher Pocock collaborates with scholars based in United Kingdom, Australia and Switzerland. Christopher Pocock's co-authors include David C. Linch, Jane F. Apperley, Kirit M. Ardeshna, David Cunningham, Andrew Jack, John Davies, John M. Goldman, Wendi Qian, John Radford and Peter Johnson and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Christopher Pocock

63 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

2013 357 citations David Cunningham, Wendi Qian et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Pocock United Kingdom	23	1.2k	1.1k	810	809	386	64	2.1k
Isabelle Plantier France	12	1.1k 0.9×	1.1k 1.0×	843 1.0×	819 1.0×	306 0.8×	22	2.2k
Kaaren K. Reichard United States	22	576 0.5×	611 0.5×	515 0.6×	413 0.5×	425 1.1×	116	1.7k
Paolo Strati United States	29	906 0.7×	1.1k 1.0×	764 0.9×	961 1.2×	115 0.3×	141	2.5k
Piero Galieni Italy	26	700 0.6×	564 0.5×	739 0.9×	706 0.9×	98 0.3×	89	1.7k
Ellen D. Remstein United States	26	1.5k 1.2×	973 0.9×	807 1.0×	985 1.2×	135 0.3×	40	2.7k
Coralie Bélanger France	21	648 0.5×	586 0.5×	1.4k 1.7×	919 1.1×	125 0.3×	44	2.2k
Barbara Grant United States	17	1.6k 1.3×	1.6k 1.4×	337 0.4×	512 0.6×	90 0.2×	32	2.4k
Carin Backlin Sweden	18	951 0.8×	587 0.5×	235 0.3×	522 0.6×	753 2.0×	28	1.9k
Patrizia Pregno Italy	18	690 0.6×	384 0.3×	989 1.2×	710 0.9×	114 0.3×	74	1.8k
Lourdes Florensa Spain	23	571 0.5×	1.1k 1.0×	1.0k 1.3×	387 0.5×	149 0.4×	120	2.0k

Countries citing papers authored by Christopher Pocock

Since Specialization

Citations

This map shows the geographic impact of Christopher Pocock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Pocock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Pocock more than expected).

Fields of papers citing papers by Christopher Pocock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Pocock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Pocock. The network helps show where Christopher Pocock may publish in the future.

Co-authorship network of co-authors of Christopher Pocock

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Pocock. A scholar is included among the top collaborators of Christopher Pocock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Pocock. Christopher Pocock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marzolini, Maria A. V., Wendi Qian, Laura Clifton‐Hadley, et al.. (2024). Quality of life in advanced‐stage, asymptomatic, non‐bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful‐waiting. British Journal of Haematology. 206(3). 876–886. 2 indexed citations

Evens, Andrew M., Joseph M. Connors, Anas Younes, et al.. (2021). Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 107(5). 1086–1094. 31 indexed citations

Wei, Andrew H., Gail J. Roboz, Hervé Dombret, et al.. (2020). CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial. Blood. 136(Supplement 1). 38–40. 6 indexed citations

Clark, Richard E., Jane F. Apperley, Dragana Milojković, et al.. (2019). De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. The Lancet Haematology. 6(7). e375–e383. 116 indexed citations

O’Brien, Stephen J., Letizia Foroni, Wendy Osborne, et al.. (2018). Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML. Blood. 132(Supplement 1). 457–457. 10 indexed citations

Pott, Christiane, Eva Hoster, Michael Unterhalt, et al.. (2018). Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients. Blood. 132(Supplement 1). 396–396. 20 indexed citations

Evens, Andrew M., Joseph M. Connors, Anas Younes, et al.. (2018). Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. Blood. 132(Supplement 1). 1618–1618. 9 indexed citations

Herold, Michael, Eva Hoster, Ann Janssens, et al.. (2017). IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL). Hematological Oncology. 35(S2). 146–147. 13 indexed citations

Clark, Richard E., Jane F. Apperley, Christopher Pocock, et al.. (2016). Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study. Blood. 128(22). 938–938. 6 indexed citations

10.

O’Brien, Stephen G., Sarah Adams, Letizia Foroni, et al.. (2014). Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML. Blood. 124(21). 517–517. 24 indexed citations

11.

Collins, Graham P., Anne Parker, Christopher Pocock, et al.. (2013). Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. British Journal of Haematology. 164(1). 39–52. 22 indexed citations

12.

Fields, Paul, Andrew Webb, Christopher Pocock, et al.. (2011). First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial. Blood. 118(21). 1634–1634. 2 indexed citations

13.

Mahmood, Shameem, Ashley R Cooper, Robin Ireland, & Christopher Pocock. (2009). Leukaemia cutis with chronic myelomonocytic leukaemia. British Journal of Haematology. 147(4). 413–413. 3 indexed citations

14.

Thornton, Patrick, C Bellas, Almudena Santón, et al.. (2005). Richter's transformation of chronic lymphocytic leukemia. Leukemia Research. 29(4). 389–395. 93 indexed citations

15.

Czepulkowski, Barbara, et al.. (2003). Mosaic trisomy 2 in myelodysplastic syndromes and acute myeloblastic leukemias. Cancer Genetics and Cytogenetics. 145(1). 78–81. 3 indexed citations

16.

Cwynarski, Kate, Rebecca Goulding, Christopher Pocock, et al.. (2001). Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions. Bone Marrow Transplantation. 28(6). 581–586. 28 indexed citations

17.

Pocock, Christopher, G. Lucas, Carolyn M. Giles, et al.. (2001). Immune neutropenia associated with anti‐human neutrophil antigen‐2a (NB1) antibodies following unrelated donor stem cell transplantation for chronic myeloid leukaemia: perpetuation by granulocyte colony‐stimulating factor. British Journal of Haematology. 113(2). 483–485. 21 indexed citations

18.

Scopes, John, et al.. (2001). Correction of stromal cell defect after bone marrow transplantation in aplastic anaemia. British Journal of Haematology. 115(3). 642–652. 22 indexed citations

19.

Kulkarni, Sarah, Sally Parker, Andrew Chase, et al.. (2000). Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).. PubMed. 60(13). 3592–8. 92 indexed citations

20.

Pocock, Christopher, M. Malone, Margaret D. M. Evans, et al.. (1995). BCL‐2 expression by leukaemic blasts in a SCID mouse model of biphenotypic leukaemia associated with the t(4;ll)(q21;q23) translocation. British Journal of Haematology. 90(4). 855–867. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact